Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages (original) (raw)

• Pollard JW . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71–78.
  Article CAS PubMed Google Scholar
• Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow? Lancet 2001; 357:539–545.
  Article CAS PubMed Google Scholar
• Coussens LM, Werb Z . Inflammation and cancer. Nature 2002; 420:860–867.
  Article CAS PubMed PubMed Central Google Scholar
• Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L . The origin and function of tumor-associated macrophages. Immunol Today 1992; 13:265–270.
  Article CAS PubMed Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P . Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42:717–727.
  Article CAS PubMed Google Scholar
• Zhang B, Wang J, Gao J, et al. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem 2009; 107:134–143.
  Article CAS PubMed Google Scholar
• Martinez FO, Sica A, Mantovani A, Locati M . Macrophage activation and polarization. Front Biosci 2008; 13:453–461.
  Article CAS PubMed Google Scholar
• Condeelis J, Pollard JW . Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124:263–266.
  Article CAS PubMed Google Scholar
• Bingle L, Brown NJ, Lewis CE . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254–265.
  Article CAS PubMed Google Scholar
• Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006; 116:2132–2141.
  Article CAS PubMed PubMed Central Google Scholar
• Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M . The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25:677–686.
  Article CAS PubMed Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A . Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549–555.
  Article CAS PubMed Google Scholar
• Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007; 110:4319–4330.
  Article CAS PubMed Google Scholar
• Mantovani A, Allavena P, Sica A . Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004; 40:1660–1667.
  Article CAS PubMed Google Scholar
• Kishimoto T . Interleukin-6: from basic science to medicine -- 40 years in immunology. Annu Rev Immunol 2005; 23:1–21.
  Article CAS PubMed Google Scholar
• Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61:8851–8858.
  CAS PubMed Google Scholar
• Salem M, Elbaz O, Zahran M, et al. Malignancy: identification of predictors of disease status and progression in patients with myeloma (MM). Hematology 2000; 5:41–45.
  Article PubMed Google Scholar
• Thavasu PW, Ganjoo RK, Maidment SA, et al. Multiple myeloma: an immunoclinical study of disease and response to treatment. Hematol Oncol 1995; 13:69–82.
  Article CAS PubMed Google Scholar
• Knupfer H, Preiss R . Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007; 102:129–135.
  Article PubMed Google Scholar
• Foti E, Ferrandina G, Martucci R, et al. IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology 1999; 57:211–215.
  Article CAS PubMed Google Scholar
• Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv Exp Med Biol 1997; 417:323–327.
  Article CAS PubMed Google Scholar
• Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160:1224–1232.
  CAS PubMed Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP . Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5:2963–2970.
  CAS PubMed Google Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150–4166.
  CAS PubMed Google Scholar
• Dendorfer U, Oettgen P, Libermann TA . Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994; 14:4443–4454.
  Article CAS PubMed PubMed Central Google Scholar
• Libermann TA, Baltimore D . Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10:2327–2334.
  Article CAS PubMed PubMed Central Google Scholar
• Zerbini LF, Wang Y, Cho JY, Libermann TA . Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 2003; 63:2206–2215.
  CAS PubMed Google Scholar
• Chinenov Y, Kerppola TK . Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20:2438–2452.
  Article CAS PubMed Google Scholar
• Milde-Langosch K . The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41:2449–2461.
  Article CAS PubMed Google Scholar
• Wisdom R, Verma IM . Proto-oncogene FosB: the amino terminus encodes a regulatory function required for transformation. Mol Cell Biol 1993; 13:2635–2643.
  Article CAS PubMed PubMed Central Google Scholar
• Shaulian E, Karin M . AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4:E131–E136.
  Article CAS PubMed Google Scholar
• Belguise K, Kersual N, Galtier F, Chalbos D . FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 2005; 24:1434–1444.
  Article CAS PubMed Google Scholar
• Ramos-Nino ME, Blumen SR, Pass H, Mossman BT . Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. Mol Cancer 2007; 6:81.
  Article PubMed PubMed Central Google Scholar
• Adiseshaiah P, Vaz M, Machireddy N, Kalvakolanu DV, Reddy SP . A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. J Cell Physiol 2008; 216:405–412.
  Article CAS PubMed PubMed Central Google Scholar
• Adiseshaiah P, Lindner DJ, Kalvakolanu DV, Reddy SP . FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth, but is insufficient to promote tumor growth in vivo. Cancer Res 2007; 67:6204–6211.
  Article CAS PubMed Google Scholar
• Andreolas C, Kalogeropoulou M, Voulgari A, Pintzas A . Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells. Int J Cancer 2008; 122:1745–1756.
  Article CAS PubMed Google Scholar
• Debinski W, Gibo DM . Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 2005; 3:237–249.
  CAS PubMed Google Scholar
• DeNardo DG, Barreto JB, Andreu P, et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91–102.
  Article CAS PubMed PubMed Central Google Scholar
• Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92:4778–4791.
  CAS PubMed Google Scholar
• Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173:3844–3854.
  Article CAS PubMed Google Scholar
• Nabarro S, Himoudi N, Papanastasiou A, et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J Exp Med 2005; 202:1399–1410.
  Article CAS PubMed PubMed Central Google Scholar
• Yu H, Kortylewski M, Pardoll D . Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41–51.
  Article CAS PubMed Google Scholar
• Asgeirsson KS, Olafsdottir K, Jonasson JG, Ogmundsdottir HM . The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 1998; 10:720–728.
  Article CAS PubMed Google Scholar
• Sehgal PB, Tamm I . Interleukin-6 enhances motility of breast carcinoma cells. EXS 1991; 59:178–193.
  CAS PubMed Google Scholar
• Selander KS, Li L, Watson L, et al. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 2004; 64:6924–6933.
  Article CAS PubMed Google Scholar
• Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M . IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 2005; 47:82–89.
  Article CAS PubMed Google Scholar